论文部分内容阅读
目的:观察不同剂量瑞舒伐他汀对急性心肌梗死合并心房颤动患者临床预后的影响。方法:急性心肌梗死合并心房颤动患者在优化的冠心病用药基础上随机分为瑞舒伐他汀10mg治疗组和20mg治疗组。在第1、3、6个月时进行随访。6个月后随机选取成功完成随访的共122例患者纳入研究。复查24h动态心电图,观察血脂变化、心功能的改变、房颤再发率、缺血相关事件的发生率及用药不良事件发生率。结果:瑞舒伐他汀10mg组与20mg组血脂TC、LDL-C及TG指标在治疗1个月及6个月后较治疗前均有明显降低(P<0.05);不同剂量瑞舒伐他汀治疗6个月后2组HR均较治疗前显著降低(P<0.05),2组左室LVDs、LVDd、LVEF、FS、SV和CO较治疗前显著改善(P<0.05);缺血相关事件的发生率20mg治疗组低于10mg治疗组(P<0.05),2组房颤的再发率、用药的安全性比较差异无统计学意义。结论:急性心肌梗死合并心房颤动的患者应用瑞舒伐他汀治疗不仅能够降低血清总胆固醇和低密度胆固醇,而且可以联合其他冠心病药物改善心功能,20mg治疗组降低缺血相关事件的发生率,但对房颤的再发率及不安全事件无明显影响,临床6个月内应用20mg瑞舒伐他汀用药安全。
Objective: To observe the effects of different doses of rosuvastatin on the clinical prognosis of patients with acute myocardial infarction complicated with atrial fibrillation. Methods: Patients with acute myocardial infarction complicated with atrial fibrillation were randomly divided into rosuvastatin 10 mg treatment group and 20 mg treatment group on the basis of optimized coronary heart disease medication. At 1, 3, 6 months follow-up. A total of 122 patients were randomly assigned to complete follow-up 6 months later. The 24-hour ambulatory electrocardiogram was reviewed. Changes of blood lipids, changes of cardiac function, recurrence of atrial fibrillation, the incidence of ischemic-related events and the incidence of adverse drug reactions were observed. Results: The levels of TC, LDL-C and TG in 10 mg and 20 mg rosuvastatin groups were significantly lower than those before treatment (P <0.05) at 1 and 6 months after treatment. Rosuvastatin with different dosages The levels of LVDs, LVDd, LVEF, FS, SV and CO in the left ventricle were significantly improved in the two groups after 6 months (P <0.05), while those in the ischemic related events The incidence of 20mg treatment group was lower than 10mg treatment group (P <0.05), two groups of atrial fibrillation recurrence rate, the safety of medication was no significant difference. Conclusions: The use of rosuvastatin in patients with acute myocardial infarction complicated with atrial fibrillation can not only lower serum total cholesterol and low density cholesterol, but also improve cardiac function in combination with other coronary heart disease drugs. The incidence of ischemic related events is reduced in 20 mg treatment group, However, the recurrence rate of atrial fibrillation and unsafe events had no significant effect, the clinical application of 20mg rosuvastatin within 6 months of drug safety.